Research programme: small molecule therapeutics - ChemDiv/Eli Lilly

Drug Profile

Research programme: small molecule therapeutics - ChemDiv/Eli Lilly

Latest Information Update: 21 Dec 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ChemDiv; Eli Lilly
  • Class Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Unspecified

Most Recent Events

  • 19 Dec 2012 ChemDiv achieves multiple milestones in its collaboration with Eli Lilly
  • 31 Jan 2004 Preclinical trials in Undefined indication in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top